2022-06-23| PolicySpecial

America’s Ongoing Battle For Lower Insulin Prices

by Reed Slater
Share To
The cost of healthcare in America is astronomical, and insulin prices are a heavy burden on millions of Americans each month. In March, the U.S. House of Representatives passed the Affordable Insulin Now Act to cap insulin prices for insured individuals to $35 a month. The bill appears optimistic for people with diabetes, but the text raises questions about who will actually benefit from lower insulin prices and who may have to pay the same as they have been.
Why Insulin Is A Focal Point For Legislation

Insulin is used to treat diabetes by helping blood sugar enter the body’s cells to create energy. It also signals the liver to store blood sugar for later use, which helps regulate normal organ function. Without insulin, patients with diabetes can develop problems like heart disease, vision loss, and kidney disease. 

GO Prime with only $1.49 now

Novartis’ CDK4/6 Inhibitor Meets Phase 3 Endpoints In Breast Cancer
BD and A*STAR collaborate to Advance Ultra-High Dimensional Analysis in Flow Cytometry for Immunology Research
Vertex and CRISPR Collaborate Again with $330 Million Diabetes Gene Editing Deal
Amway Applauded by Frost & Sullivan for Capitalizing on Innovative Competitive Strategies to Drive Differentiation in Its Home Water Treatment Solution in APAC
BJ Bioscience Announces Clinical Collaboration with MSD to Evaluate BJ-001 in Combination with KEYTRUDA® (pembrolizumab)
35% Of Better Therapeutics’ Staff to be Cut to Extend the Company’s Runway
Pharming’s Joenja Racks Up FDA Approval For Rare Primary Immunodeficiency
Scroll to Top